The year in charts

The year in charts

Tuesday, April 25, 2023 @ 7:00 am

Capital investments in Swiss biotech companies 2012-2022

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Total Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022 — Note: The 2022 data in above tables is based on information that was available up until March 31, 2023. At this time, some of the companies had not yet disclosed
their financial figures for 2022. Therefore some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e. Q3 or Q4 2022).

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Public Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Private Swiss Biotech Companies

Number of biotech companies in Switzerland 2013-2022

Number of employees in Swiss R&D biotech companies 2020-2022

Tags

You may also be interested in

Active fraud campaign — updated warning for Swiss Biotech Day 2026

We are tracking an ongoing and escalating fraud campaign targeting Swiss Biotech Association members and Swiss Biotech Day participants. Multiple fraudulent domains and Gmail accounts have already been identified and reported to their registrars and hosts; several have been taken down, but new ones continue to appear. Please read this alert carefully and share it within your organization.
April 16, 2026

Pharvaris: Evidence for the potential of combined therapy for bradykinin-mediated angioedema

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), presented data evaluating safety margins of administration of deucrictibant immediate-release
April 20, 2026

Cosmo flash update: Positive 12-month phase III topline results

April 15, 2026

ten23 health expands commercial activities opening office in Japan

ten23 health, the human-centric and sustainable strategic CDMO partner of choice for the pharmaceutical industry and biotech start-ups today announced the expansion of its commercial activities in the APAC area with the opening of a new office in Tokyo, Japan. This strategic move marks a significant milestone in the company’s global growth and further strengthens its ability to serve biotech and
April 15, 2026

InSphero launches platform for early gastrointestinal toxicity assessment

New Offering Integrates DOPPL’s Patient-Derived Intestinal Organoid Technology with InSphero’s Proven Standardized Screening Model
April 14, 2026

Pharvaris: 2025 financial results and business update

Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026 Timeline for submission of NDA dossier of deucrictibant IR for on-demand treatment of HAE attacks remains on-track in 1H2026 Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH atta
April 2, 2026